Clopidogrel pretreatment in PCI: Absolute requirement or obsolete myth?

International Journal of Cardiology

Volumn 146, Issue 3, 2011, Pages 305-310

  Alexopoulos, Dimitrios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Antiplatelet treatment; Clopidogrel; PCI

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PLACEBO;

ANGIOCARDIOGRAPHY; BLEEDING; DRUG DOSAGE FORM COMPARISON; DRUG RESISTANCE; DRUG SAFETY; HUMAN; INFLAMMATION; LOADING DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; HUMANS; PLATELET AGGREGATION INHIBITORS; PREOPERATIVE CARE; TICLOPIDINE;

EID: 79151472673     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.06.019     Document Type: Review

References (63)

1. B. Jarvis, and K. Simpson Clopidogrel: a review of its use in the prevention of atherothrombosis Drugs 60 2000 347 377
2. P. Savi, J.M. Pereillo, and M.F. Uzabiaga Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 2000 891 896
3. P.C. Kam, and C.M. Nethery The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments Anaesthesia 58 2003 28 35
4. M.J. Quinn, and D.J. Fitzgerald Ticlopidine and clopidogrel Circulation 100 1999 1667 1672
5. S.R. Mehta, S. Yusuf, and R.J. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
6. S.R. Steinhubl, P.B. Berger, and J.T. Mann III Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
7. S.R. Steinhubl, P.B. Berger, D.M. Brennan, and E.J. Topol Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention J Am Coll Card 47 2006 939 943
8. I. Muller, M. Seyfarth, and S. Rudiger Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement Heart 85 2001 92 93
9. P.A. Gurbel, K.P. Bliden, K.A. Zaman, J.A. Yoho, K.M. Hayes, and U.S. Tantry Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR ρLΑΤΕLETS) study Circulation 111 2005 1153 1159
10. P.A. Gurbel, C.C. Cummings, C.R. Bell, A.B. Alford, A.K. Meister, and V.L. Serebruany Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the plavix reduction of new thrombus occurrence (PRONTO) trial Am Heart J 145 2003 239 247
11. S. Silber, P. Albertsson, and F.F. Aviles Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur Heart J 26 2005 804 847
12. S.B. King III, S.C. Smith Jr., and J.W. Hirshfeld Jr. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention J Am Coll Cardiol 51 2008 172 209
13. J.P. Bassand, C.W. Hamm, and D. Ardissino Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur Heart J 28 2007 1598 1660
14. T. Cuisset, C. Frere, and J. Quilici Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting J Am Coll Card 48 2006 1339 1345
15. G. Patti, G. Colonna, V. Pasceri, L.L. Pepe, A. Montinaro, and G. Di Sciascio Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Circulation 111 2005 2099 2106
16. R.M. Wolfram, R.L. Torguson, and Hassani Clopidogrel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention Am J Cardiol 97 2006 984 989
17. Mehta SR on behalf of the CURRENT study investigators. CURRENT OASIS 7: A 2 × 2 factorial randomized trial of optimal clopidogrel and aspirin dosing in patients with ACS undergoing an early invasive strategy with intent for PCI. 2009, Barcelona ESC.
18. G. Montalescot, G. Sideris, and C. Meuleman A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation. Inflammation and Ongoing Necrosis) trial J Am Coll Card 48 2006 931 938
19. N. von Beckcrath, D. Taubert, G. Pogatsa-Murray, F. Schomig, A. Kastrati, and A. Schomig Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation I 12 2005 2946 2950
20. M. Lotrionte, G.G. Biondi-Zoccai, and P. Agostoni Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention Am J Card 100 2007 1199 1206
21. A. Kastrati, N. Von Beckerath, A. Joost, G. Pogatsa-Murray, O. Gorchakova, and A. Schomig Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy Circulation 110 2004 1916 1919
22. J.P. Collet, J. Silvain, and A. Landivier Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose. The reload with clopidogrel before coronary angioplasty in subjects treated long term with dual antiplatelel therapy (RELOAD) study Circulation 118 2008 1225 1233
23. G. Di Sciascio, G. Patti, V. Pasceri, G. Colonna, F. Mangiacapra, and A. Montinaro Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial Eur Heart J 2010 10.1093/eurheartj/ehq081
24. P.L.L. Lallier, G. Ducrocq, and N. Pranno Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: Results from the PREPAIR randomized study J Am Coll Card 51 2008 1066 1072
25. D.L. Kandzari, P.B. Berger, and A. Kaslrati Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization J Am Coll Card 44 2004 2133 2136
26. P.A. Davlouros, A. Arseniou, and G. Hahalis Timing of clopidogrel loading before percutaneous coronary intervention in clopidogrel-naïve patients with stable or unstable angina: a comparison of 2 strategies Am Heart J 158 2009 585 591
27. P. Widimsky, Z. Motovska, and S. Simek Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8 Eur Heart J 29 2008 1495 1503
28. G. Patti, V. Pasceri, and G. Colonna Is 600 mg in-lab clopidogrel loading equivalent to "upstream" pre-treatment in patients undergoing percutaneous coronary intervention? Results of the ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. Late breaking clinical trials, TCT sessions October 2007 Available from: www.cardiosource.com/img/armyda501.ppt
29. D.N. Feldman, F. Fakorede, R.M. Minutello, G. Bergman, I. Moussa, and S.C. Wong Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes Am J Cardiol 105 2010 323 332
30. L.I. Kapetanakis, D.A. Mcdlam, and K.R. Petro Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae? Circulation 113 2006 1667 1674
31. R.H. Hongo, J. Ley, and S.E. Dick The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting J Am Coll Card 40 23 2002 1 7
32. J.S. Berger, C.B. Frye, Q. Harshaw, F.H. Edwards, S.R. Steinhubl, and R.C. Becker Impact of clopidogrel in patients with acute coronary syndrome requiring coronary artery bypass surgery J Am Coll Card 52 2008 1693 1701
33. F.G. Kushner, M. Hand, and S.C. Smith Jr. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
34. P.J. Vlaar, T. Svilaas, and K. Damman Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction Circulation 118 2008 1828 1836
35. M.S. Sabatine, C.P. Cannon, and C.M. Gibson Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study JAMA 294 2005 1224 1232
36. A. Kastrati, J. Mehiili, and H. Schuhlen A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel N Engl J Med 350 2004 232 238
37. A. Kastrati, J. Mehilli, and F.J. Neumann Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pre-treatment: the ISAR-REACT 2 randomised trial JAMA 295 2006 1531 1538
38. J. Saw, A.M. Linkoff, and W. DeSmet Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy J Am Coll Card 44 2004 1194 1199
39. G.W. Stone, H.D. While, and E.M. Ohman Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial Lancet 369 2007 907 919
40. H.D. While, K.M. Ohman, and A.M. Lincoff Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention. 1-year results from the ACUITY trial J Am Coll Card 52 2008 807 814
41. P.A. Gurbel, and K.P. Bliden Durability of platelet inhibition by clopidogrel Am J Cardiol 91 2003 1123 1125
42. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
43. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
44. P.A. Gurbel, R.C. Becker, K.G. Mann, S.R. Steinhubl, and A.D. Michelson Platelet function monitoring in patients with coronary artery disease J Am Coll Cardiol 50 2007 1822 1834
45. P.A. Gurbel, and U.S. Tantry Clopidogrel resistance? Thromb Res 120 2007 311 321
46. W.C. Lau, P.A. Gurbel, and P.B. Watkins Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 2004 166 171
47. J.S. Hulot, A. Bura, and E. Villard Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
48. T. Cuisset, C. Frere, and J. Quilici High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
49. W. Hochholzer, D. Trenk, and H.P. Bestehorn Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 2006 1742 1750
50. P. Buonamici, R. Marcucci, and A. Migliorini Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 49 2007 2312 2317
51. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
52. G. Patti, A. Nusca, K. Mangiacapra, I. Gatto, A. D'Ambrosio, A. D'Ambrosio, and G. DiSciascio Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. Results of the ARMYDA-PRO Study J Am Coll Card 52 2008 1128 1133
53. R. Marcucci, A.M. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
54. D. Trenk, W. Hochholzer, and M.F. Fromm Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
55. J.-S. Hulot, A. Bura, and E. Villard Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
56. C. Frere, T. Cuisset, and P.E. Morange Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
57. J.W. Van Werkum, C.A. van der Stelt, T.H. Seesing, C.M. Hackeng, and J.M. ten Berg A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention J Thromb Haemost 4 2006 2516 2518
58. R. Paniccia, E. Antonucci, and A.M. Gori Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients J Thromb Haemost 5 2007 1839 1847
59. A. Pena, J.P. Collet, and J.S. Hulot Can we override clopidogrel resistance? Circulation 119 2009 2854 2857
60. M.E. Bertrand, H.J. Rupprecht, P. Urban, A.H. Gershlick for the CLASSICS Investigators Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) Circulation 102 2000 624 629
61. D.P. Vivekananthan, D.L. Bhatt, and D.P. Chew Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention Am J Card 94 2004 358 360
62. P.A. Gurbel, K.P. Bliden, and U.S. Lantry Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study J Am Coll Card 48 2006 2186 2191
63. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150